Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kabos

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Nucleic Acids Research|November 30, 2018
Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq librariesKent A Riemondy, Monica Ransom, Christopher Alderman, et al.
Neuro-Oncology|April 13, 2023
Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasisMaria J Contreras-Zárate, Karen L F Alvarez-Eraso, Jenny A Jaramillo-Gómez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerAditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Cancer Medicine|October 16, 2020
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer CenterJennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, et al.
NPJ Breast Cancer|November 6, 2022
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b studyHope S Rugo, Peter Kabos, J Thad Beck, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cellsAshley V Ward, Duncan Riley, Kirsten E Cosper, et al.
Breast Cancer Research : BCR|March 7, 2025
Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cellsAshley V Ward, Duncan Riley, Kirsten E Cosper, et al.
Frontiers in Oncology|May 31, 2017
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerAnastasia A Ionkina, John J Tentler, Jihye Kim, et al.
Molecular Carcinogenesis|December 2, 2021
Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancerHeather M Brechbuhl, Mengyu Xie, Etana G Kopin, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Nucleic Acids Research|November 30, 2018
Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq librariesKent A Riemondy, Monica Ransom, Christopher Alderman, et al.
Neuro-Oncology|April 13, 2023
Short-term topiramate treatment prevents radiation-induced cytotoxic edema in preclinical models of breast-cancer brain metastasisMaria J Contreras-Zárate, Karen L F Alvarez-Eraso, Jenny A Jaramillo-Gómez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerAditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Cancer Medicine|October 16, 2020
Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer CenterJennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, et al.
NPJ Breast Cancer|November 6, 2022
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b studyHope S Rugo, Peter Kabos, J Thad Beck, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cellsAshley V Ward, Duncan Riley, Kirsten E Cosper, et al.
Breast Cancer Research : BCR|March 7, 2025
Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cellsAshley V Ward, Duncan Riley, Kirsten E Cosper, et al.
Frontiers in Oncology|May 31, 2017
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerAnastasia A Ionkina, John J Tentler, Jihye Kim, et al.
Molecular Carcinogenesis|December 2, 2021
Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancerHeather M Brechbuhl, Mengyu Xie, Etana G Kopin, et al.
Pageof 10